Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Intermediate Risk Acute Myeloid Leukemia”

66 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 66 results

Large-scale testing (Phase 3)Study completedNCT02473146
What this trial is testing

Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4

Who this might be right for
Acute Myeloid Leukemia
Versailles Hospital 225
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07643636
What this trial is testing

Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML

Who this might be right for
AML (Acute Myeloid Leukemia)
Dongguan People's Hospital 46
Early research (Phase 1)Study completedNCT01127009
What this trial is testing

Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)+12 more
Case Comprehensive Cancer Center 3
Large-scale testing (Phase 3)Enrolling By InvitationNCT07537257
What this trial is testing

VEN+IDAC vs IDAC in AML

Who this might be right for
AML (Acute Myelogenous Leukemia)
Guangdong Second Provincial General Hospital 232
Large-scale testing (Phase 3)Looking for participantsNCT02416388
What this trial is testing

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Who this might be right for
Acute Myeloid Leukemia (AML)
University Hospital, Angers 3,100
Large-scale testing (Phase 3)Enrolling By InvitationNCT07651163
What this trial is testing

Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy

Who this might be right for
Acute Myeloid Leukemia (AML)Lisaftoclax
First Affiliated Hospital of Zhejiang University 450
Large-scale testing (Phase 3)Study completedNCT00260832
What this trial is testing

Trial of Decitabine in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Eisai Inc. 485
Testing effectiveness (Phase 2)WithdrawnNCT03515707
What this trial is testing

Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaMinimal Residual Disease Negativity
Fred Hutchinson Cancer Center
Large-scale testing (Phase 3)Looking for participantsNCT04168502
What this trial is testing

Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Who this might be right for
Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 414
Testing effectiveness (Phase 2)WithdrawnNCT05829434
What this trial is testing

Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Neoplasm
Uwe Platzbecker
Large-scale testing (Phase 3)Study completedNCT02870777
What this trial is testing

MRD-directed Therapy for Low-risk and Intermediate-risk AML.

Who this might be right for
Acute Myeloid LeukemiaMinimal Residual Disease
Nanfang Hospital, Southern Medical University 743
Testing effectiveness (Phase 2)Looking for participantsNCT05260528
What this trial is testing

CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

Who this might be right for
Acute Myeloid Leukemia
Centre Hospitalier Universitaire de Nice 248
Early research (Phase 1)Study completedNCT02485535
What this trial is testing

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

Who this might be right for
Acute Myeloid Leukemiade Novo Myelodysplastic SyndromeMyelodysplastic Syndrome+2 more
University of Chicago 12
Testing effectiveness (Phase 2)Study completedNCT02428543
What this trial is testing

Ponatinib for FLT3-ITD Acute Myelogenous Leukemia

Who this might be right for
Acute Myeloid Lukemia
Versailles Hospital 49
Early research (Phase 1)Study completedNCT02070458
What this trial is testing

Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Adult Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Case Comprehensive Cancer Center 30
Large-scale testing (Phase 3)Active Not RecruitingNCT03897127
What this trial is testing

Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

Who this might be right for
Acute Myeloid Leukemia
University of Ulm 882
Testing effectiveness (Phase 2)Study completedNCT01690507
What this trial is testing

Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）

Who this might be right for
MDSAML
Chinese PLA General Hospital 29
Large-scale testing (Phase 3)Not Yet RecruitingNCT07761702
What this trial is testing

Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML

Who this might be right for
AML (Acute Myelogenous Leukemia)
Shanghai Jiao Tong University School of Medicine 132
Not applicableLooking for participantsNCT06529250
What this trial is testing

Intermediate-dose HAD Regimen for CEBPA Double-mutated AML

Who this might be right for
AML
Institute of Hematology & Blood Diseases Hospital, China 148
Large-scale testing (Phase 3)Study completedNCT00962767
What this trial is testing

Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission

Who this might be right for
Leukemia, Myelocytic, Acute
Wyeth is now a wholly owned subsidiary of Pfizer 168
Next Page